My watch list  


News Evista

  • Analysis of R&D portfolio management

    At the core of portfolio management lies the need to identify and prioritise the most profitable products/projects in the R&D pipeline with the aim of maximising return on investment. For the pharmaceutical industry, the difficulty of quantifying the uncertainties associated with product development more

  • Lilly Outlines Its Strategy to Become the Pharmaceutical Growth Company of the Decade

    Eli Lilly and Company will review with members of the investment community its strategic and operational plans for industry-leading long-term growth. Growth Strategy "Our growth strategy has been to either discover or collaborate with partners on drug candidates with best-in-class or first-in-clas more

Publications Evista

  • Patent watch

    Patent watch Nature Reviews Drug Discovery 9, 756 (2010). doi:10.1038/nrd3291 Author: Charlotte Harrison Evista patents upheldIn a dispute against generics manufacturer Teva, Eli Lilly and Company (Lilly) has seen the majority of its patents that protect Evista (raloxifene) upheld by the U more


This is where you can add this topic to your personal favourites

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE